Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa.
Hunjan, Manrup Kaur Bardhan, Ajoy Harper, Natasha Langman, Gerald Ajayi, Bamidele Suresh, Vijay Heagerty, Adrian H M
Hunjan, Manrup Kaur
Bardhan, Ajoy
Harper, Natasha
Langman, Gerald
Ajayi, Bamidele
Suresh, Vijay
Heagerty, Adrian H M
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-06-09
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.
Citation
Hunjan MK, Bardhan A, Harper N, Langman G, Ajayi B, Suresh V, Heagerty AHM. Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2022 Aug;47(8):1588-1590. doi: 10.1111/ced.15228. Epub 2022 Jun 9
Type
Article